Advancing novel cancer therapeutics through next generation liquid biopsy solutions
We aim to help our partners accelerate precision oncology across cancer indications and therapeutic modalities with research to clinical trials and, ultimately, registration and commercial launch.
Our team brings together biopharma and companion diagnostics expertise with biomarker, drug-diagnostic co-development, and commercialization experience.
Our partnerships deliver cancer detection and classification results with the potential to analyze and monitor epigenetic signatures from early to advanced stage cancer.
Data from GRAIL studies have demonstrated analytically validated performance, and robust analytical sensitivity, specificity, and precision.
We leverage the combination of GRAIL’s unique methylation-based liquid biopsy platform and biologically motivated machine learning capabilities.
Together, our technology and customizable approach enables applications in the post-cancer diagnosis space for disease prognostication, risk stratification, minimal residual disease (MRD) detection and recurrence and relapse monitoring across many cancer types.
Our newly available post-diagnosis cancer research use only solution provides our partners the opportunity to test novel, high-potential clinical research applications with access to our blood-only liquid biopsy assay.
Our solution estimates tumor burden using methyl variant allele fraction (MVAF) and can be used for longitudinal monitoring and surveillance. GRAIL studies have analytically validated performance, demonstrating strong specificity, and precision.
Our blood-only approach eliminates challenges with obtaining tissue samples and avoids bias due to tumor heterogeneity or tumor escape mechanisms.
Our solution's analytical sensitivity and low input requirements are supportive for retrospective research studies.
Partner with GRAIL for your oncology diagnostic testing needs across biomarker discovery, retrospective studies and companion diagnostic tests to accelerate your efforts to bring impactful solutions.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The RUO test was developed, and its performance characteristics were determined by GRAIL. The RUO test is For Research Use Only, Not for Diagnostic Procedures. GRAIL’s RUO product offerings have not been cleared or approved by the Food and Drug Administration.